Bladder Cancer Trial, Recruiting NCT06511141 Sponsor: Axonics, Inc. Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT06511141
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older at the time of joining the trial
  • You are able to fill out bladder diaries and patient questionnaires
  • Your main bladder problem is overactive bladder (OAB), meaning you experience sudden, strong urges to urinate, leaking urine due to those urges, or needing to urinate very frequently
  • You are willing and able to sign a consent form, follow the study requirements, and attend all check-up visits for up to 1 year

Who may not be able to join:

  • The doctor running the trial does not consider you a suitable candidate for any reason
  • You have had a prostate procedure or treatment within the last 6 months
  • You have a neurological condition that could affect how your bladder works, such as a stroke, epilepsy, multiple sclerosis, Parkinson's disease, significant nerve damage, or a spinal cord injury
  • You have previously had a sacral nerve stimulation device implanted, even if it is no longer active
  • You have previously been treated with an implantable tibial nerve stimulation device
  • You responded positively to a needle-based tibial nerve stimulation treatment (a non-surgical nerve treatment) within the last 3 months
  • You tried a sacral nerve stimulation device on a trial basis and a doctor determined it did not work for you
  • You have a significant health condition that may interfere with the study or make it hard to evaluate the results, as determined by your doctor
  • You have uncontrolled diabetes
  • You have a known allergy to any of the materials used in the device, including titanium, zirconia, polyurethane, epoxy, or silicone

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gita Ghadimi, OD, Boston Scientific Corporation

Phone: 714-225-0903

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Axonics, Inc.
Registry
ClinicalTrials.gov
Start date
22 October 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Adverse event reporting (Safety); Performance/Effectiveness - Reduction in UUI or UF episodes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov